Literature DB >> 29106357

Position Paper on laboratory testing for patients on direct oral anticoagulants. A Consensus Document from the SISET, FCSA, SIBioC and SIPMeL.

Armando Tripodi1, Walter Ageno2, Marcello Ciaccio3, Cristina Legnani4, Giuseppe Lippi5, Cesare Manotti6, Rossella Marcucci7, Marco Moia1, Benedetto Morelli8, Daniela Poli9, Agostino Steffan10, Sophie Testa11.   

Abstract

Although direct oral anticoagulants (DOAC) do not require dose-adjustment on the basis of laboratory test results, the measurement of their anticoagulant effect is useful in special situations. This position paper issued by the Italian Scientific Societies that are mainly involved in the management of patients on DOAC is aimed at providing guidance to care-givers on which tests should be used and the situations in which testing is useful. The guidance is based on the data from the literature so far available and/or on consensus among experts.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29106357      PMCID： PMC6125231          DOI： 10.2450/2017.0124-17

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


  45 in total

1.  The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study.

Authors:  A Tripodi; V Chantarangkul; C Guinet; M M Samama
Journal:  J Thromb Haemost       Date:  2011-01       Impact factor: 5.824

Review 2.  The laboratory and the direct oral anticoagulants.

Authors:  Armando Tripodi
Journal:  Blood       Date:  2013-04-05       Impact factor: 22.113

3.  Effect of standardized perioperative dabigatran interruption on the residual anticoagulation effect at the time of surgery or procedure.

Authors:  J D Douketis; G Wang; N Chan; J W Eikelboom; S Syed; R Barty; K A Moffat; F A Spencer; M Blostein; S Schulman
Journal:  J Thromb Haemost       Date:  2016-01-04       Impact factor: 5.824

4.  To measure or not to measure direct oral anticoagulants before surgery or invasive procedures: comment.

Authors:  A C Spyropoulos; A Al-Badri; M W Sherwood; J D Douketis
Journal:  J Thromb Haemost       Date:  2016-10-24       Impact factor: 5.824

5.  Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time.

Authors:  Helen Mani; Christian Hesse; Gertrud Stratmann; Edelgard Lindhoff-Last
Journal:  Thromb Haemost       Date:  2011-06-09       Impact factor: 5.249

Review 6.  Management of Patients on Non-Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association.

Authors:  Amish N Raval; Joaquin E Cigarroa; Mina K Chung; Larry J Diaz-Sandoval; Deborah Diercks; Jonathan P Piccini; Hee Soo Jung; Jeffrey B Washam; Babu G Welch; Allyson R Zazulia; Sean P Collins
Journal:  Circulation       Date:  2017-02-06       Impact factor: 29.690

7.  Idarucizumab for Dabigatran Reversal.

Authors:  Charles V Pollack; Paul A Reilly; John Eikelboom; Stephan Glund; Peter Verhamme; Richard A Bernstein; Robert Dubiel; Menno V Huisman; Elaine M Hylek; Pieter W Kamphuisen; Jörg Kreuzer; Jerrold H Levy; Frank W Sellke; Joachim Stangier; Thorsten Steiner; Bushi Wang; Chak-Wah Kam; Jeffrey I Weitz
Journal:  N Engl J Med       Date:  2015-06-22       Impact factor: 91.245

8.  Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study.

Authors:  S Testa; C Legnani; A Tripodi; O Paoletti; V Pengo; R Abbate; L Bassi; P Carraro; M Cini; R Paniccia; D Poli; G Palareti
Journal:  J Thromb Haemost       Date:  2016-10-15       Impact factor: 5.824

9.  The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.

Authors:  Joachim Stangier; Karin Rathgen; Hildegard Stähle; Dietmar Gansser; Willy Roth
Journal:  Br J Clin Pharmacol       Date:  2007-05-15       Impact factor: 4.335

10.  Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate.

Authors:  J Douxfils; J-M Dogné; F Mullier; B Chatelain; Y Rönquist-Nii; R E Malmström; P Hjemdahl
Journal:  Thromb Haemost       Date:  2013-06-20       Impact factor: 5.249
View more
  25 in total

Review 1.  The vexed question of whether or not to measure levels of direct oral anticoagulants before surgery or invasive procedures.

Authors:  Armando Tripodi; Francesco Marongiu; Marco Moia; Gualtiero Palareti; Vittorio Pengo; Daniela Poli; Domenico Prisco; Sophie Testa; Maria Zanazzi
Journal:  Intern Emerg Med       Date:  2018-04-26       Impact factor: 3.397

2.  Dabigratan-related acute agranulocytosis.

Authors:  Ahmad Al-Khaffaf; Francesco Frattini; Cinzia Sissa; Elda Mimiola; Massimo Franchini
Journal:  Blood Transfus       Date:  2019-01-21       Impact factor: 3.443

3.  A clinical conundrum: to measure or not measure direct oral anticoagulants before a surgery or procedure?

Authors:  James D Douketis; Mansoor Radwi
Journal:  Intern Emerg Med       Date:  2018-08-24       Impact factor: 3.397

Review 4.  Direct oral anticoagulants for extended treatment of venous thromboembolism: insights from the EINSTEIN CHOICE study.

Authors:  Davide Imberti; Fulvio Pomero; Daniela Mastroiacovo
Journal:  Blood Transfus       Date:  2019-04-30       Impact factor: 3.443

5.  Testing direct oral anticoagulants: embedding in structured long-term care.

Authors:  Hugo Ten Cate
Journal:  Blood Transfus       Date:  2017-10-22       Impact factor: 3.443

6.  Usefulness of initial plasma dabigatran concentration to predict rebound after reversal.

Authors:  Nicolas Gendron; Juliette Gay; Marine Lemoine; Pascale Gaussem; Agnès Lillo-Le-Louet; David M Smadja
Journal:  Haematologica       Date:  2018-02-22       Impact factor: 9.941

7.  Drug plasma level measurement in management of severe bleeding during direct oral anticoagulant treatment: case report and perspective.

Authors:  Dimitriy Arioli; Davide Donelli; Lorenzo Morini; Maria Cristina Leone; Emanuele Alberto Negri
Journal:  Intern Emerg Med       Date:  2018-05-03       Impact factor: 3.397

8.  Direct oral anticoagulant monitoring: what laboratory tests are available to guide us?

Authors:  Ravi Sarode
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

9.  Position paper on the safety/efficacy profile of direct oral anticoagulants in patients with chronic kidney disease. Consensus document from the SIN, FCSA and SISET.

Authors:  Elvira Grandone; Filippo Aucella; Doris Barcellona; Giuliano Brunori; Giacomo Forneris; Paolo Gresele; Marco Marietta; Daniela Poli; Sophie Testa; Armando Tripodi; Simonetta C Genovesi
Journal:  Blood Transfus       Date:  2020-08-06       Impact factor: 3.443

10.  Determination of the cut-off prothrombin time to estimate plasma rivaroxaban overdose status.

Authors:  Bohyun Kim; Seongsoo Jang; Yu-Jin Lee; Nuree Park; Young-Uk Cho; Chan-Jeoung Park
Journal:  J Thromb Thrombolysis       Date:  2020-02       Impact factor: 2.300
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.